These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. The metabolism of omega-3 polyunsaturated fatty acids in the eye: the possible role of docosahexaenoic acid and docosanoids in retinal physiology and ocular pathology. Bazan NG Prog Clin Biol Res; 1989; 312():95-112. PubMed ID: 2529559 [TBL] [Abstract][Full Text] [Related]
32. Psoriasis and the arachidonic acid cascade. Ikai K J Dermatol Sci; 1999 Nov; 21(3):135-46. PubMed ID: 10527374 [TBL] [Abstract][Full Text] [Related]
33. Cannabinoid receptors as therapeutic targets. Mackie K Annu Rev Pharmacol Toxicol; 2006; 46():101-22. PubMed ID: 16402900 [TBL] [Abstract][Full Text] [Related]
34. New insights into endocannabinoid degradation and its therapeutic potential. Bari M; Battista N; Fezza F; Gasperi V; Maccarrone M Mini Rev Med Chem; 2006 Mar; 6(3):257-68. PubMed ID: 16515464 [TBL] [Abstract][Full Text] [Related]
36. The expanding field of cannabimimetic and related lipid mediators. Bradshaw HB; Walker JM Br J Pharmacol; 2005 Feb; 144(4):459-65. PubMed ID: 15655504 [TBL] [Abstract][Full Text] [Related]
37. Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality. Hwang J; Adamson C; Butler D; Janero DR; Makriyannis A; Bahr BA Life Sci; 2010 Apr; 86(15-16):615-23. PubMed ID: 19527737 [TBL] [Abstract][Full Text] [Related]
38. Therapeutic opportunities through modulation of the endocannabinoid system. Makriyannis A; Mechoulam R; Piomelli D Neuropharmacology; 2005 Jun; 48(8):1068-71. PubMed ID: 15885714 [No Abstract] [Full Text] [Related]